Accelerated underwriting continues to expand across life products, but questions remain around mortality impact and scalability. This session examines how carriers combine third-party data, prescription history, financial records, and predictive models to reduce fluid requirements while maintaining risk confidence. What products are best suited for acceleration? How are carriers measuring performance? And how does reinsurer alignment influence deployment? This discussion is focused on real underwriting implementation decisions.